Powered Presicion Drug Design HANGZHOU, China and LONDON, March 07, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

“There’s pretty good preclinical evidence that there is synergistic activity when radiation therapy, and possibly also alkylating chemotherapy, is combined with a WEE1 inhibitor,” says Roth.

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor ...

"Developing new therapies for this subset of ovarian cancer patients is urgently needed. DENALI Part 1b results are exciting as they show that the WEE1 inhibitor, azenosertib, is active in a Cyclin E1 ...